Introduction {#s1}
============

Tendon disorders include both acute and chronic diseases, such as tendinopathy. It is know that the tendon tissue is poorly cellularized, with 5% of the normal tissue occupied by tenocytes that produce the extracellular matrix (ECM), based on type I collagen. Furthermore, along with tenocytes, the human tendons are also composed by tendon stem/progenitor cells (TSPCs), that guarantee to the tendon the ability to repair and regenerate and help in maintaining the homeostasis (Bi et al., [@B6]).

There is a debate on the role of inflammation in the production of degenerative changes in the tendon tissue (Abate et al., [@B1]; Cook and Purdam, [@B16]). However, recent new findings demonstrated the presence of inflammatory elements in pathologic tendons, as well as the activation of matrix metallo-proteinases, and the involvement of mediators such as substance P, vascular endothelial growth factor (VEGF), and cyclo-oxigenase type II (COX2; De Mattei et al., [@B21]). Tendon healing normally occurs in three different phases: the acute inflammatory phase, for up to 3--7 days, in which the neo-angiogenesis occurs, followed by the proliferative phase, for up to 21 days, when intrinsic cell proliferation of epitenon and endotenon tenocytes and extrinsic invasion of cells from the surrounding sheath and synovial occur, simultaneously with collagen, fibronectin, and elastin production, and the third remodeling phase, for up to 2 years (De Palma and Rapali, [@B22]; Abate et al., [@B1]). Different studies evaluated the molecular mechanisms that promote the healing process, such as metalloproteinases (MMPs) and MMPs with thrombospondin motifs (ADAMTs), in association with their tissue inhibitors (TIMPs; Sharma and Maffulli, [@B75]). Particularly MMP-9 and MMP-13 participate in collagen degradation only, while MMP-2, MMP-3, and MMP-14 are involved in both collagen degradation and remodeling (Riley et al., [@B67]). Indeed, different growth factors may be involved in neo-vascularization and stimulation of fibroblast and tenocytes, such as VEGF, TGF-β1, fibroblast growth factors (FGFs), and Scleraxis (Scx; Sharma and Maffulli, [@B76]). Furthermore, Nitric Oxide (NO) may also be involved in the healing process (Murrell, [@B53]).

In this scenario, different conservative treatments were proposed to treat tendon degeneration and tendinopathy. In this manuscript, we will analyze the rationale of mechanical stimulation by Extracorporeal shock wave (ESW) and Pulsed electromagnetic fields (PEMF) for tendon regeneration, and its possible role in the treatment of different tendinopathies.

Extracorporeal shock wave therapy (ESWT) for tendon\'s pathology {#s2}
================================================================

Shock waves\' definition and mechanism of action
------------------------------------------------

A shock wave is a special, non-linear type of pressure wave with a short rise time (around 10 μs) and a frequency ranging from 16 to 20 MHz (Ogden et al., [@B56]). These waves have a positive and negative (low-pressure) phase. In the first phase, ESW may hit an interface, with their reflection, or may gradually pass and become absorbed. The second phase causes cavitation at the tissue interfaces, with bubbles formation that subsequently implode, generating a second wave (Ogden et al., [@B56]). The propagating wave increase the tissue density and, as a consequence, transmit direct mechanical perturbations to the tissue with effects on cell membrane polarization, radical formation, cell proliferation, and growth factor production. Low energy ESW with a shock number ranging from 200 to 300 impulses seem most suited for enhancing cell proliferation and metabolism and, subsequently, for clinical applications.

There are two type of shockwave therapy: the focused shockwave therapy (FSWT) and the radial shockwave therapy (RSWT). *Focused shockwaves* are characterized by a pressure field that converges at a selected depth in the body tissues, where the maximal pressure is reached. FSWT can be generated using three methods: electro hydraulic (EH), electromagnetic (EM), and piezoelectric (PE). In all the cases the wave is generated in water, because of the acoustic impedance of water and biologic tissue are similar (van der Worp et al., [@B87]). The difference between the three methods of generation is the time at which the shockwave forms (Coleman and Saunders, [@B15]). RSWs are characterized by a diverging pressure field, which reach the maximal pressure at the source, and they are not generated in water (van der Worp et al., [@B87]). A recent *in vitro* study of Notarnicola et al. pointed out the negative effect of RWS on bone metabolism (Notarnicola et al., [@B55]), while some evidences in literature suggests a positive effect of RWS on the enthesis of plantar fascia and on the degenerated areas of Achilles tendon structure (van der Worp et al., [@B87]).

The supposed mechanism of action of ESW rely on conformational changes in membrane proteins, such as the integrins and, subsequently, on intracellular signal generation that modify gene expression and release of growth factors. Indeed, shock waves-induced repair phenomenon is observed in presence of increased level of IL-6, which is able to stimulate fibroblast production of collagen and ECM components (Waugh et al., [@B96]). A transient increase of IL-1b expression and a prolonged increase of IL-8 one was also described, consistent with a modulation of initial inflammatory phase. Following these observations, it is not surprising that ESW may stimulate matrix metalloproteinase (MMP) activity. Specifically, an increased expression of MMP-2 and the pro-MMP-9 was demonstrated. Considering the well-known low level of basal repair and MMP activity (i.e., MMP-9) in degenerative tendinopathy, these concepts support the statement that ESWT may also favor tendon repair by increasing pro-MMP forms availability, allowing for greater pathological tendon remodeling by ECM-degrading enzymes and, ultimately, favoring tendon tissue regeneration. Indeed, MMPs are also capable to activate latent TGF-β sequestered in the ECM. Nevertheless, a great inter-individual variability in the response of MMP to ESW was observed. This may represent a possible biological explanation for the variations in clinical success rates of ESWT in different tendinopathies and may be a clue for recognize and identify the population of responders and non-responders to ESWT.

Vetrano et al. demonstrated that ESWT up-regulates the expression of collagen (mainly type I) and stimulate cell proliferation in primary cultured human healthy tenocytes (Vetrano et al., [@B90]). However, the same group compared the results of ESWT (at the dose of 0.14 mJ/mm^2^) in cultured healthy and pathologic tenocytes, demonstrating that Scx and collagen type I were significantly diminished in the pathologic tenocytes cultures. These results indicate that the natural trigger for healing may be delayed by ESW treatment, in order to promote cellular repair (Leone et al., [@B46]). Pre-clinical studies showed that ESW are able to increase VEGF, VEGF receptor Flt-1, endothelial nitric oxide synthase (eNOS), and proliferating cell nuclear antigen (PCNA) expression, consistent with the initial neo-vascularization process. Improved blood supply and early vascularity is associated with the initial leukocyte infiltration and the subsequent metabolism of the fibers in the putative tendon pathological area by means of ECM-degrading enzymes (Bosch et al., [@B9]). This early phase is followed by an ESW-driven transitory increase in TGF-β1 expression, later followed by persistent IGF-I expression, that leads to a controlled inhibition of macrophages-induced ECM degradation and inflammation and an enhanced ECM and collagen type I synthesis (Visco et al., [@B92]). Tendon cells proliferation was also associated in this repair sequence, as well as endogenous lubricin production by fibroblasts and tenocytes following growth factors stimulation (i.e., TGF-β1; Zhang, [@B100]). The ultimate result of ESWT is a simulation of cell metabolism, which may induce healing process in injured areas of the tendons (Chen et al., [@B12]).

Recently, soft-focused ESWT was proposed, in order to deliver the energy in a larger area (Kuo et al., [@B43]). In the *in vitro* study of, de Girolamo et al. the effect of soft-focused ESWT were evaluated on a primary culture of healthy human tendon cells in adherent monolayer culture. The rationale of the study was to maintain cell-to-cell contacts and cell interactions with the ECM during ESWT, as it is a crucial point in the mechano-trasduction process. Furthermore, physical forces, such as soft-focused ESWT, may influence conformational changes in membrane proteins, such as integrines, resulting in an intra-cellular signal with a modification of gene expression and growth factors release (de Girolamo et al., [@B19]). At the molecular level, the authors evaluated the relationship between IL-1β and the production of MMPs, considered to be responsible for ECM degradation and tendon degeneration (Clegg et al., [@B14]). Both MMP-3 and 13 were not influenced by soft-focused ESW exposure, suggesting that the increased levels of IL-1β were not correlated with the ECM degradation. On the other hand, an increased expression of SCX, collagen type I genes (regulated by SCX expression), TGF-β, anti-inflammatory cytokines IL-6 and Il-10 and VEGF (stimulated by IL-6 and IL-10) was observed during the first 7 days after exposure to soft-focused ESW, although SCX transcription decreased rapidly during the first 4 days. All these results suggest that soft-focused ESWT may positively modulate the initial beneficial inflammatory phase of the tendon healing process (Visco et al., [@B92]) and "normalize" the anabolic activities of tendon cells.

Although the lack of sure evidence, ESWT may also be efficient in reducing calcifications in tendon structure (van der Worp et al., [@B87]).

Clinical results of ESWT in tendon\'s pathology treatment
---------------------------------------------------------

ESWT is reported to be an effective treatment in different chronic tendon pathologies.

Shoulder
--------

In 2014 Bannuru et al. published a systematic review on 28 Randomized Controlled Trials (RCT) comparing high-energy vs. low-energy ESWT or placebo for treatment of calcific or non-calcific tendinitis of the shoulder. The authors concluded that high-energy ESWT was significantly better than placebo in reducing pain and improving function in calcific tendinopathy, while no differences were detected between ESWT and placebo in non-calcific tendinopathy (Bannuru et al., [@B4]).

Huisstede et al. in 2011, in a systematic review, included 17 RCTs about ESWT vs. placebo in calcific and non-calcific rotator cuff tendinopathy. The authors concluded for strong evidence toward the best effectiveness of high-ESWT in calcific rotator cuff tendinopathy. Furthermore, no differences between the treatments were found in non-calcific rotator cuff tendinopathy (Huisstede et al., [@B36]). Similar results were reported in the systematic review by Harniman et al. ([@B34]). The single studies are summarized in Table [1](#T1){ref-type="table"}.

###### 

**Summary of literature studies on ESWT, Extra-corporeal Shock Waves Therapy; RSWT, radial shockwave therapy**.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Authors and Year**            **Pathology**                                 **Number of patients**                                                                      **Level**   **Type ESWT**                                                                                         **Follow-up**          **Outcomes**
  ------------------------------- --------------------------------------------- ------------------------------------------------------------------------------------------- ----------- ----------------------------------------------------------------------------------------------------- ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **SHOULDER**                                                                                                                                                                                                                                                                                                       

  Loew et al., [@B47]             Calcific tendinitis of the shoulder           195 (80 divided in 4 groups with different regimens, 115 divided into one or two session)   II          \- High-ESWT EFD: 0.30 mJ/mm^2^ (high) one session---double\                                          Not reported           The results showed energy-dependent success. With 58% of pain relief after two high-energy session
                                                                                                                                                                                        - Low-ESWT: 0.1 mJ/mm^2^(high) one session---double\                                                                         
                                                                                                                                                                                        Control (no treatment; *n* = 20)                                                                                             

  Schmitt et al., [@B72]          Non-calcific supraspinatus tendinitis         40                                                                                          II          \- High-ESWT 0.11 mJ/mm^2^(*n* = 20)\                                                                 12 weeks               Increased function and a reduction of pain in both groups (*p* \< or = 0.001). The authors did not recommend ESWT for the treatment of tendinitis of supraspinatus
                                                                                                                                                                                        - Sham ESWT (*n* = 20)                                                                                                       

  Speed et al., [@B78]            Non-calcific supraspinatus tendinosis6        74                                                                                          II          \- ESWT: 0.12 mJ/mm^2^(medium; *n* = 34)\                                                             Not reported           No significant difference between the treatments in terms of pain. The authors concluded on no benefit of ESWT in patients with non-calcific tendonitis
                                                                                                                                                                                        - ESWT: minimum: 0.04 mJ/mm^2^ (low; *n* = 40)                                                                               

  Haake et al., [@B33]            Calcific tendinitis of the supraspinatus      50                                                                                          II          \- ESWT: focus on calcific deposit: 0.78 mJ/mm^2^(high; *n* = 25)\                                    1 year                 Significantly better Constant and Murley score in ESWT at the calcified area under fluoroscopic control
                                                                                                                                                                                        - ESWT: focused on tuberculum majus: 0.78 mJ/mm^2^ (high; *n* = 25)                                                          

  Pan et al., [@B59]              Calcific tendinitis of the shoulder           63                                                                                          II          \- High-ES WT 2 Hz 2000 shock waves, 2 sessions, 14 days apart 0.26--0.32 mJ/mm^2^(*n* = 33)\         6 months               Better outcomes VAS and Constant score in the ESWT group compared to TENS group
                                                                                                                                                                                        - TENS 3x/week 20 min for 4 weeks (*n* = 30)                                                                                 

  Gerdesmeyer et al., [@B30]      Calcific rotator cuff tendinopathy            96                                                                                          II          \- High-ESWT (1500 pulses 0.32 mJ/mm^2^; *n* = 48)\                                                   1 year                 High-ESWT and low-ESWT provided a beneficial effect on pain, function and calcifications\' size. However, high-ESWT appeared to be superior compared to low-ESWT
                                                                                                                                                                                        - Sham ESWT (*n* = 48)                                                                                                       

  Perlick et al., [@B62]          Calcific tendinitis of the shoulder           80                                                                                          II          \- ESWT: 0.23 mJ/mm^2^(medium; *n* = 40)\                                                             1 year                 Improvement in Constant and Murley scores. However, the disintegration of calcific deposits is dose-dependent
                                                                                                                                                                                        - ESWT: 0.42 mJ/mm^2^ (high; *n* = 40)                                                                                       

  Peters et al., [@B63]           Calcific tendinosis of the shoulder           61                                                                                          II          \- High level ESWT: 0.44 mJ/mm^2^ (*n* = 31)\                                                         6 months               ESWT in calcific tendinitis of the shoulder is very effective, without significant side effects at 0.44 mJ/mm^2^
                                                                                                                                                                                        - Medium level ESWT: 0.15 mJ/mm^2^ (*n* = 30)                                                                                

  Cosentino et al., [@B17]        Chronic calcific tendinitis of the shoulder   135                                                                                         IV          ESWT 0.03 mJ/mm^2^ (4 sessions)                                                                       1 month                Improvement in the Constant and Murley score, with partial resorption of the deposits in 44.5% of patients, and complete resorption in 22.3% of patients

  Krasny et al., [@B42]           Calcific supraspinatus tendinitis             80                                                                                          II          \- High-ESWT plus Ultrasound-guided needling (*n* = 40)\                                              4.1 months (average)   Ultrasound-guided needling in combination with high-ESWT is more effective compared to ESWT alone, with higher rates of deposits elimination, better clinical results and lower need for surgery
                                                                                                                                                                                        - High-ESWT only (200 impulses followed by 2500 pulses, 0.36 mJ/mm^2^(*n* = 40)                                              

  Sabeti-Aschraf et al., [@B70]   Calcific tendinitis of the shoulder           50                                                                                          II          \- ESWT: 0.08 mJ/mm^2^ Point of max tenderness (*n* = 25)\                                            12 weeks               Both groups had significant improvements in the Constant and Murley score and VAS score. However, the navigation group showed better results
                                                                                                                                                                                        - ESWT: 0.08 mJ/mm^2^Point of max tenderness by computer-assisted navigation device (*n* = 25)                               

  Moretti et al., [@B52]          Rotator cuff calcifying tendinitis            44                                                                                          IV          Four sessions of medium-ESWT (0.11 mJ/mm^2^) ESWT administered with an electromagnetic lithotripter   6 months               70% of satisfactory functional results. Disappearance of the deposits in 50% of the cases

  Cacchio et al., [@B11]          Calcific tendinitis of the shoulder           50                                                                                          II          \- ESWT 4 sessions at 1-week intervals, with 25,00 pulses per session, 0.10 mJ/mm^2^ (*n* = 25)\      6 months               Better functional results in the RSWT group
                                                                                                                                                                                        - ESWT 4 sessions at 1-week intervals, total number of pulses: 25 (*n* = 25)                                                 

  Albert et al., [@B3]            Calcific tendinitis of the shoulder           80                                                                                          II          \- ESWT: max 0.45 mJ/mm^2^(high; *n* = 40)\                                                           110 days               High-ESWT group had significant better results, but with the calcific deposit unchanged in size in the majority of patients
                                                                                                                                                                                        - ESWT: 0.02-0.06 mJ/mm^2^ (low; *n* = 40)                                                                                   

  Hsu et al., [@B35]              Calcific tendinitis of the shoulder           46                                                                                          II          \- High-ESWT: 0.55 mJ/mm^2^(*n* = 33\                                                                 1 year                 No significant difference between Gärtner type I and type II groups in the Constant score (*P* \>.05). ESWT are effective in the treatment of calcific tendinitis with negligible complication
                                                                                                                                                                                        - Sham ESWT (*n* = 13)                                                                                                       

  Rebuzzi et al., [@B66]          Calcific tendinitis of the supraspinatus      46                                                                                          IV          \- Arthroscopic extirpation (*n* = 22)\                                                               24 months              No differences in UCLA scores. ESWT have similar results compared to arthroscopy
                                                                                                                                                                                        - Low\                                                                                                                       
                                                                                                                                                                                        - ESWT (*n* = 24)                                                                                                            

  Schofer et al., [@B73]          Non-calcific shoulder tendinopathy            40                                                                                          II          \- High-ESWT-1 0.78 mJ/mm^2^(*n* = 20)\                                                               12 weeks               Statistically significant improvement in both groups, without statistically significant differences between high-ESWT and low-ESWT
                                                                                                                                                                                        - High-ESWT-2 0.33 mJ/mm^2^(*n* = 20)                                                                                        

  Ioppolo et al., [@B37]          Supraspinatus Calcifying Tendinitis           46                                                                                          II          \- ESWT at an energy level of 0.20 mJ/mm^2^\                                                          6 months               Better results in the first group of treatment (Constant Murley Scale = CMS)
                                                                                                                                                                                        - ESWT at an energy level of 0.10 mJ/mm^2^                                                                                   

  Galasso et al., [@B29]          Non-calcifying supraspinatus tendinopathy     20                                                                                          II          \- ESWT\                                                                                              12 weeks               ESWT groups showed better CMS score, without any side effect
                                                                                                                                                                                        - sham control group                                                                                                         

  **PATELLAR TENDINOPATHY**                                                                                                                                                                                                                                                                                          

  Peers et al., [@B61]            Chronic patellar tendinopathy                 27                                                                                          III         \- Surgical treatment (*n* = 13)\                                                                     6 months               ESWT showed comparable outcomes compared to surgery
                                                                                                                                                                                        - ESWT (*n* = 14)                                                                                                            

  Taunton and Khan, [@B82]        Chronic patellar tendinopathy                 30                                                                                          II          \- ESWT (*n* = 20)\                                                                                   Not reported           ESWT is effective in adjunction with eccentric exercises in treating patellar tendinopathy
                                                                                                                                                                                        - ESWT with energy-absorbing pad (*n* = 10)                                                                                  

  Wang et al., [@B95]             Chronic patellar tendinopathy                 50                                                                                          II          \- ESWT (0.18 mJ/mm^2^ energy flux density; *n* = 27)\                                                2-3 years              ESWT is more effective compared to conservative treatment
                                                                                                                                                                                        - Conservative treatment (*n* = 23)                                                                                          

  Vulpiani et al., [@B94]         Jumper\'s knee                                73                                                                                          IV          \- ESWT (4 sessions 1500--2500 impulses,energy varying between 0.08 and 0.44 mJ/mm^2^)                Not reported           Satisfactory outcomes in ESWT treatment for jumper\'s knee

  Zwerver et al., [@B102]         Severe patellar tendinopathy                  19                                                                                          IV          Patient guided Piezo-electric, focused ESWT                                                           3 months               Patient guided Piezo-electric ESWT without local anesthesia is a safe and well-tolerated treatment for severe patellar tendinopathy

  Zwerver et al., [@B103]         Patellar tendinopathy in athletes             62                                                                                          I           \- ESWT (*n* = 31)\                                                                                   1 year                 No benefit of ESWT over placebo in treatment of patellar tendinopathy in in-season athletes
                                                                                                                                                                                        - Sham ESWT (*n* = 31)                                                                                                       

  Furia et al., [@B28]            Chronic patellar tendinopathy                 66                                                                                          III         \- Radial low-ESWT (*n* = 33)\                                                                        1 year                 The percentage of "excellent" functional outcomes was significantly higher in the ESWT group
                                                                                                                                                                                        - Conservative treatment (*n* = 33)                                                                                          

  **ELBOW PATHOLOGY**                                                                                                                                                                                                                                                                                                

  Rompe et al., [@B68]            Chronic lateral epicondylitis of the elbow    30                                                                                          II          \- ESWT (0.16 mJ/mm^2^)\                                                                              1 year                 Each group showed significant improvement in the pain and functional scores. The authors concluded that ESWT may be an effective conservative treatment method for unilateral chronic tennis elbow
                                                                                                                                                                                        - ESWT (0.16 mJ/mm^2^) plus cervical manual therapy                                                                          

  Maier et al., [@B48]            Chronic lateral tennis elbow                  42                                                                                          IV          ESWT                                                                                                  18.6 months            Good clinical performances after ESWT. Male patients performed better than female ones. In female patients, Magnetic Resonance Imaging (MRI) may predict the results of ESWT

  Speed et al., [@B77]            Lateral epicondylitis                         75                                                                                          II          \- ESWT at 0.12 mJ/ mm^2^\                                                                            1 year                 No significant difference between the groups, concluding that the placebo effect of ESWT may be considerable
                                                                                                                                                                                        - Sham therapy                                                                                                               

  Melegati et al., [@B51]         Lateral epicondylitis                         41                                                                                          II          \- ESWT (Lateral tangential focusing)\                                                                Not reported           No differences between the techniques
                                                                                                                                                                                        - ESWT (tangential focusing)                                                                                                 

  Furia, [@B26]                   Chronic lateral epicondylitis                 36                                                                                          IV          ESWT                                                                                                  Not reported           77.8% were rated excellent or good on the Roles and Maudsley scale

  Chung et al., [@B13]            Chronic lateral epicondylitis                 60                                                                                          II          \- ESWT + stretching program\                                                                         1 year                 No differences in clinical outcomes
                                                                                                                                                                                        - Sham therapy                                                                                                               

  Staples et al., [@B79]          Lateral epicondylitis                         68                                                                                          II          −3 ESWT treatments\                                                                                   6 months               Little evidence in favor of ESWT in the treatment of lateral epicondylitis
                                                                                                                                                                                        - 3 treatments at a subtherapeutic dose                                                                                      

  Radwan et al., [@B64]           Resistant tennis elbow                        46                                                                                          II          \- high\                                                                                              1 year                 Excellent and good results were achieved in 65.5% of patients in ESWT group and 74.1% in the percutanous group
                                                                                                                                                                                        - ESWT (0.22 mJ/mm^2^; *n* = 29)\                                                                                            
                                                                                                                                                                                        - Percutanous tenotomy (*n* = 27)                                                                                            

  Gunduz et al., [@B32]           Lateral epicondylitis                         59                                                                                          II          \- Physical therapy\                                                                                  6 months               All the treatment had favorable effects on pain and grip strength in the early period
                                                                                                                                                                                        - A single corticosteroid injection\                                                                                         
                                                                                                                                                                                        - ESWT                                                                                                                       

  Lee et al., [@B45]              Medial and lateral epicondylitis              22                                                                                          III         \- ESWT group (0.06--0.12 mJ/mm^2^; *n* = 12)\                                                        8 weeks                Both the treatments were effective for medial and lateral epicondylitis
                                                                                                                                                                                        - local steroid injection group (*n* = 10)                                                                                   

  Notarnicola et al., [@B54]      Epicondylitis                                 26                                                                                          IV          ESWT                                                                                                  Not reported           Progressive improvement in pain during the follow-up, with decrease in grip strength, especially in the dominant limb

  Trentini et al., [@B84]         Lateral epicondylitis                         36                                                                                          IV          Focused ESWT                                                                                          24.8 months            75.7% of positive response. Focal ESWT is a valuable and safe solution in case of lateral epicondylitis, both in newly diagnosed and previously treated cases

  **FOOT PATHOLOGY**                                                                                                                                                                                                                                                                                                 

  Furia, [@B27]                   Insertional Achilles tendinopathy             88                                                                                          II          \- ESWT group; 0.21 mJ/mm^2^; total energy flux density, 604 mJ/mm^2^ (*n* = 35)\                     1 year                 Better Roles and Maudsley results in the ESWT group. NO differences if a local anesthesia was performed or not before the ESWT session
                                                                                                                                                                                        - Non-operative therapy (*n* = 33)                                                                                           

  Rasmussen et al., [@B65]        Chronic Achilles tendinopathy                 48                                                                                          II          \- active ESWT\                                                                                       12 weeks               Better results in the active ESWT group
                                                                                                                                                                                        - sham ESWT                                                                                                                  

  Vulpiani et al., [@B93]         Achilles tendinopathy                         115                                                                                         IV          ESWT (0.08 and 0.40 mJ/mm^2^)                                                                         1 year                 76% of satisfactory results at the last follow-up

  Saxena et al., [@B71]           Achilles tendinopathy                         74                                                                                          IV          ESWT                                                                                                  1 year                 74.8% of patients improved 1 year after surgery, with significant improvement of the Roles and Maudsley score

  Kim et al., [@B40]              Plantar fasciitis                             10                                                                                          IV          ESWT                                                                                                  6 months               Decreased plantar fascia thickness, spasticity, and pain and increased gait ability after ESWT
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Patellar tendinopathy
---------------------

Van Leeuwen et al. in 2009 published a systematic review describing the results of ESWT in patellar tendinopathy, collecting seven RCTs on ESWT vs. placebo. The authors concluded on positive results using ESWT in treating patellar tendinopathy, but most of the studies had different frequency of treatments, application, and shockwave generation, energy level and method of localization (van Leeuwen et al., [@B88]). However, Zwerver et al. in 2011 published a RCT on 62 symptomatic athletes affected by patellar tendinopathy treated either with ESWT or placebo, concluding for no beneficial effects of ESWT (Zwerver et al., [@B103]). Due to these conflicting reports, further studies are needed to clarify the value of ESWT for patellar tendinopathy. Again, the most recent studies are summarized in Table [1](#T1){ref-type="table"}.

Elbow
-----

Buchbinder et al. in 2005 published a systematic review regarding the effectiveness and safety of ESWT for lateral elbow pain. The authors included nine trials, randomizing 1006 participants to ESWT or placebo and one trial including 93 participants randomized into ESWT or steroid injection. They concluded that steroid injections were more effective compared to ESWT (Buchbinder et al., [@B10]). Recently, Trentini et al. reported the results on 36 patients affected by lateral epicondylitis and treated with focal ESWT. At a mean follow-up of 24.8 months, the authors described a positive response to the treatment in 75.7% of the patients (Trentini et al., [@B84]). These studies outlines that, the clinical efficacy of ESWT for the treatment of medial and lateral epycondylitis is still controversial, as shown in the papers reported in Table [1](#T1){ref-type="table"}.

Foot pathology
--------------

In 2013 Al-Abbad et al. published a systematic review including six studies (4 RCTs) and evaluating the efficacy of ESWT for Achilles tendinitis treatment. The authors concluded that ESWT was effective for Achilles tendinopathy at a minimum 3 months\' follow-up (Al-Abbad and Simon, [@B2]). Other studies pointed out similar conclusions as shown in Table [1](#T1){ref-type="table"}.

Recently, Kim et al. analyzed the efficacy of ESWT also for plantar fasciitis in stroke patients, reporting on reduced tension in the plantar fascia, and observing pain relief and improved gait ability (Kim et al., [@B40]; Table [1](#T1){ref-type="table"}). Their results are similar to other recent studies (Park et al., [@B60]; Yin et al., [@B99]; Gollwitzer et al., [@B31]; Konjen et al., [@B41]; Mardani-Kivi et al., [@B49]), and allows for considering ESW a precious therapeutic modality for treating acute or recalcitrant plantar fasciitis with acceptable success rate ranging from 50% to 80%, at least at a short term follow-up.

Pulsed electromagnetic fields (PEMF) for tendon\'s pathology {#s3}
============================================================

Pulsed electromagnetic fields (PEMF) definition and mechanism of action
-----------------------------------------------------------------------

PEMF are characterized by frequencies at the low end of the electromagnetic spectrum, ranging between 6 and 500 Hz (Bassett, [@B5]). Another feature of PEMF waveforms is the rate of change: higher rate of changes (Tesla/seconds) are able to induce biological currents in the tissue, with peculiar biological effects (Juutilainen and Lang, [@B39]). Furthermore, it was demonstrated that low-frequency fields are non-ionizing and athermal (Rubik, [@B69]).

Different types of waveforms were associated to PEMF: asymmetric, biphasic, sinusoidal, quasi-rectangular, or quasi-triangular in shape (Bassett, [@B5]). In 1979, the Food and Drug Administration (FDA) approved both quasi-rectangular and quasi-triangular PEMF as safe and effective for the treatment of fractures and their sequelae (Bassett, [@B5]).

There are two methods in which PEMF can be applied to biological tissues: capacitive or inductive coupling. Capacitive coupling does not involve any contact with the body. However, in direct capacitive coupling, an electrode has to be placed on the skin of the opposite side (Trock, [@B85]). On contrary inductive coupling does not require the electrodes to be in direct contact with the skin, because the magnetic field produces an electric field that, in turn, produces a current in the conductive tissues of the body (Stiller et al., [@B80]; Trock, [@B85]).

Similarly to ESW, PEMF are physical stimuli that produce membrane disturbances and activation of multiple intracellular pathways. Indeed, formation of lipidic "nanopores" in the plasma membrane following PEMF exposure may explain the conduction of ions into the cell from the extracellular space, specifically Calcium ions (Ca). Furthermore, a direct effect of PEMF on phospholipids within the plasma membrane has been postulated, with a subsequent production of several second messengers, initiating multiple intracellular signal transduction pathways, as well as a further activation of protein kinase C (Semenov et al., [@B74]; Tolstykh et al., [@B83]).

Nevertheless, PEMFs have been recently connected to other cell activation pathways. In particular, the ligand-independent activation of epidermal growth factor receptor (EGFR) and other members of the receptor tyrosine kinase family were observed, with subsequent stimulation of intracellular signaling as the MAPK (mitogen-activated protein kinases)/ERK (extracellular signal-regulated kinases) pathway, with subsequently activation of intracellular mitogenic pathway (Wolf-Goldberg et al., [@B97]).

Recent studies outlined the expression of canonical Wnt signaling proteins (Wnt1/ lipoprotein receptor-related protein 5 LRP5/beta-catenin) in cell derived from a mesenchymal lineage and exposed to PEMF (Jing et al., [@B38]; Zhou et al., [@B101]). At this regard, the presence of beta-catenin seems particularly important with respect to other settings, in which this protein is linked to cell plasticity and proliferation, as in the superficial zone of articular cartilage (Yasuhara et al., [@B98]; Marmotti et al., [@B50]).

Finally, the exposure to PEMF induces early up-regulation of adenosine receptor A~2A~ and A~3~. Adenosine receptor A~2A~ and A~3~ are able to reduce PGE2 and pro-inflammatory cytokine IL-6 and IL-8 release and to inhibit the activation of transcription factor NF-kB, a key regulator of inflammatory responses (Vincenzi et al., [@B91]), as well as to positively interfere in several cell activities as cell proliferation (Varani et al., [@B89]).

Taken together, all these observations suggest a possible role of PEMF for "tenocyte activation" (Dingemanse et al., [@B24]; de Girolamo et al., [@B20]). This may be achieved by two main mechanisms: (i) limiting the catabolic effects of pro-inflammatory cytokines such as IL-1, IL-6, and IL-8 and (ii) increasing ECM production, cytokine release and cell proliferation (De Mattei et al., [@B21]; Fassina et al., [@B25]; Ongaro et al., [@B57]; de Girolamo et al., [@B18]). Recent studies of de Girolamo et al. (de Girolamo et al., [@B18], [@B20]) demonstrated that human tendon cells proliferation was enhanced after PEMF treatment, and in particular, that a 1.5 mT-PEMF treatment was able to up-regulate SCX, VEGF-A, and COL1A1 gene expression. Moreover, the treated tendon cells showed, after 2 days, a higher release of IL-6, IL-10, and TGF-β. These effects are essential for tendon metabolism, inducing increased elastin and fibronectin production, increased cell proliferation and neo-angiogenesis.

Clinical results of PEMF in tendon\'s pathology treatment
---------------------------------------------------------

Despite the lack of recent literature sustaining a long-term positive effect of PEMF in treating shoulder and elbow tendon disorders (Uzunca et al., [@B86]; Bisset et al., [@B8]; Dingemanse et al., [@B24]), a positive effect of PEMF in reducing lateral epicondylitis pain was described at a short term follow-up (3 months). Moreover, several reports back in the 80\'s proposed a putative role in the treatment of rotator cuff disease and lateral epicondylitis (Binder et al., [@B7]; Devereaux et al., [@B23]). A very recent study by Osti et al. described a possible role of PEMF after rotator cuff repair as an adjuvant treatment, in order to reduce local inflammation, post-operative joint swelling and stiffness, and recovery time, as well as to induce pain relief. A significant short term (up to 5 months) positive effect was observed in PEMF treated patients, but the authors did not observe any clinical and functional improvement at a longer (2 years) follow-up (Osti et al., [@B58]).

Some suggestions for the use of PEMF for treating human Achilles tendon pathologies come only from preclinical animal studies. Strauch et al. in 2006 analyzed the effect of PEMF on the biomechanical strength of rat Achilles\' tendons at 3 weeks after transection and surgical repair, with an increase in tensile strength of up to 69% 3 weeks after the surgery (Strauch et al., [@B81]). Previously, Lee et al. in 1997 analyzed the possible role of pulsed magnetic fields (PMF) and (PEMF) in the healing process of Achilles tendon inflammation in the rat (Lee et al., [@B44]).

Conclusion {#s4}
==========

Mechanical stimulation by means of ESW and PEMF seems to be favorable for tendon regeneration in preclinical and *in vitro* studies. Indeed, a beneficial effect has been demonstrated on tendon resident cells at a cellular level. Increased cell proliferation and the production of the immuno-regulatory cytokines and growth and angiogenic factors was observed *in vitro*, consistent with an overall "tenocyte activation" favoring tendon healing process. Conversely, there is still a lack of strong evidences on ESW and PEMF when dealing with clinical settings. The efficacy of ESWT is demonstrated for the treatment of calcific rotator cuff tendinopathy, while it is still debated its role in the treatment of other tendon disorders, such as patellar tendinopathy and lateral epicondylitis. PEMF seem to exert positive clinical effects toward shoulder and elbow tendon disorders only at a short term follow up. While basic science research continues to show encouraging results, further *in vivo* human studies are undoubtedly necessary to confirm the clinical efficacy of mechanical stimulation by means of PEMF and ESW for the treatment of tendon disorders.
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